 
 
 
     
 
 
    Official Title : A Phase 2/3, Randomized, Double -Blind, Vehicle -Controlled  Study to Determine 
the Efficacy and Safety of AP0302 in the  Treatment of Delayed Onset Muscle 
Soreness (DOMS)  
 
NCT Number : NCT 03852459 
 
Applicant/ IND: 
Aponia Laboratories, Inc.  
 
Version Date : 02-Jul-2018  
 
 
 
  
 
CONFIDENTIAL  Aponia Laboratories, Inc.  
 
Protocol Amendment 3 AP-007 Version: 02-Jul-2018 3 2 STUDY SYNOPSIS 
TITLE A Phase 2/3, Randomized , Double -Blind, Vehicle -Controlled Study to 
Determine the Efficacy  and Safety of AP0302  in the Treatment of 
Delayed Onset Muscle Soreness (DOMS)  
PROTOCOL NUMBER  AP-007 
INVESTIGATOR AND 
STUDY SITE  , MD  
 
 
OBJECTIVE(S)  Primary objective : 
‚Ä¢ To evaluate the efficacy of AP0302 5%  (  
 in DOMS of the elbow flexors in generally healthy 
subjects  
Secondary objective:  
‚Ä¢ To evaluate the safety of AP0302  in DOMS  of the elbow 
flexors in generally healthy subjects 
STUDY DESIGN  This is a Phase 2/3 , randomized, single- center, double -blind, 
vehicle -controlled, parallel -group study designed to determine the 
efficacy and safety of AP0302  (  
 for the treatment of muscle 
pain/soreness  associated with DOMS.   Enough subjects will be 
screened to randomize 250 subjects.  
Subjects will be screened up to 28 days prior to Day 1 .  After 
completing the info rmed consent and screening  processes, the 
following  procedures will be completed: physical examination, 
medical history and concomitant medications collections, 
inclusion/exclusion criteria review, baseline laboratory testing, 12 -lead 
electrocardiogram (EC G), pregnancy testing (females of child -bearing 
potential), drug and alcohol testing , and vital sign measurements.  
Subjects who meet initial inclusion/exclusion criteria will be scheduled to return to the research center to  undergo an exercise 
regimen  
.   
Between  following the end of the exercise regimen, 
subjects will return to the clinic to be evaluated for eligibility into the 
active treatment phase of the study. 
To qualify  for randomization, subjects mus t report a  
PI
[INVESTIGATOR_306606]
I
CBI
CBI
CBI
CBI
CBI
CONFIDENTIAL  Aponia Laboratories, Inc.  
 
Protocol Amendment 3 AP-007 Version: 02-Jul-[ADDRESS_375359], DOSE, 
AND MODE OF 
ADMINISTRATION  
REFERENCE 
THERAPY, DOSE AND 
MODE OF ADMINISTRATION  
ELIGIBILITY 
CRITERIA Inclusion criteria  
1. Generally healthy subjects of either gender aged 18 to 55 years 
(inclusive) at the time of signing the study informed consent form 
(ICF).  The subject is in good health, with no clinically significant 
medical conditions, as determined by [CONTACT_306619], physical examination, ECG, and 
screeni ng laboratory results.   
2. Female subjects of childbearing potential (women who have 
experienced menarche and are not postmenopausal or permanently sterilized [by [CONTACT_306620], hysterectomy, or bilateral 
salpi[INVESTIGATOR_1656]]) will agree to use medically acceptable methods of 
contraception including but not limited to abstinence, birth control 
pi[INVESTIGATOR_255590], vaginal rings, diaphragm with vaginal spermicide, 
condom with vaginal s permicide, intrauterine device , and 
progestin implant or injection (used con sistently for 3 months prior 
to study dosing) throughout the study and for [ADDRESS_375360] 
dose of IP.  Male subjects will agree to refrain from sperm 
donation and female subjects from egg donation throughout the 
CBI
CBI
CONFIDENTIAL  Aponia Laboratories, Inc.  
 
Protocol Amendment 3 AP-007 Version: 02-Jul-[ADDRESS_375361] has a history of experiencing muscle pain/soreness after 
moderately strenuous exercise.  
4. Subject has a body mas s index  between [ADDRESS_375362] (IRB).  
6. Subject is willing and able to complete the standardized exercise regimen.  
Post-Exercise:  
[ADDRESS_375363]  a job or hobby [CONTACT_306621] (eg , rock climbers,  movers, 
construction workers).  
3. Subjects with a history of surgery, significant trauma, significant 
musculoskeletal pathology, or significant nervous system pathology in the neck or in the non -dominant  arm or shoulder  that 
is likely to be exacerbated by [CONTACT_306622], in the opi[INVESTIGATOR_306607] . 
4. Subjects with any condition,  in the investigator‚Äôs judgment , that 
may interfere with local tolerability assessments in the area of study drug application, including recently applied tattoos.  
5. History of any muscle disorder (eg , statin myopathy or any 
muscular dystrophy), neuropathy, fibromyalgia, rhabdomyolysis , 
or chronic fatigue syndrome.  
6. Presence of another painful physical condition that, in the opi[INVESTIGATOR_8574], may confound study assessments.  
7. Any contraindication to t he use of ibuprofen, or any nonsteroidal 
anti-inflammatory drug (NSAID) or cyclooxygenase -2 inhibitor, 
or aspi[INVESTIGATOR_248], including any history of asthma or recent history of 
gastritis or gastrointestinal bleeding.  
8. Presence of an allergy or intolerance to any NSA ID or aspi[INVESTIGATOR_306608].  
9. Presence of a latex allergy ( customized  armband  components 
contain latex ). 
10. Any skin condition that could potentially inter fere with 
absorption of drug (eg , keloid, rash, dermatitis).  
11. Have received chronic opi[INVESTIGATOR_306609], Inc.  
 
Protocol Amendment 3 AP-007 Version: 02-Jul-[ADDRESS_375364] received an opi[INVESTIGATOR_306610] 30 days prior to Day 1 . 
13. Routine use (defined as 3 out of 7 days per week) of any 
analgesic drug (over -the-counter  [OTC] or prescription).   
14. Consumption of any medication (prescription or OTC  
medications, vitamins, minerals, and dietary supplements ) within 
2 weeks prior to Day 1.  Exception: continuing hormonal 
contraception and hormone replacement therapy is  allowed.   
15. Any history of drug or alcohol abuse  (according to the 
investigator‚Äôs judgment)  in the prior [ADDRESS_375365]‚Äôs ability  to safely  complete 
all study procedures (including  the exercise regimen ) or might 
interfere with the efficacy results of the study.  
EFFICACY VARIABLES Primary Endpoint: Sum of the time -weighted pain intensity 
differences from baseline with m ovement (SPID MOVE ) over 0- [ADDRESS_375366]-T0 (SPID MOVE  0-24 hr ). 
Key Secondary Endpoints:  
1. SPID MOVE  over the following intervals: [ADDRESS_375367] -T0. 
Other Secondary Endpoints:  
1. Sum of time -weighted differences from baseline in muscle 
stiffness with movement  (SSID MOVE ) over the following 
intervals:  0-6, 6-12, 0- 12, 12- 24, 0- 24, 0- 36, 24- 48, and 0- [ADDRESS_375368] -T0. 
2. Total relief with movement (TOTPAR MOVE ) 0-[ADDRESS_375369]‚Äôs global assessment of  study medication  assessed at 
approximately [ADDRESS_375370]-T 0 (or upon early termination, if 
applicable).  
SAFETY VARIABLES  ‚Ä¢ AEs 
‚Ä¢ Local tolerability assessments  
‚Ä¢ Clinical laboratory assessments  
‚Ä¢ Physical examination, including neuromuscular and strength 
assessment of upper extremit ies 
‚Ä¢ Vital signs (blood pressure, heart rate, temperature, and 
respi[INVESTIGATOR_697]) 
‚Ä¢ ECGs  
CONFIDENTIAL  Aponia Laboratories, Inc.  
 
Protocol Amendment 3 AP-007 Version: 02-Jul-2018 8 ANALYSIS 
POPULATIONS  Three analysis populations will be used: 
Safety Population:  all subjects who receive at least 1 dose of study 
drug.   
Full Analysis Set (FAS):  all subjects who are randomized, receive at 
least [ADDRESS_375371]-baseline efficacy 
assessment.  
Per Protocol Set (PPS):  all subjects in the FAS without a major 
protocol deviation.  The sponsor will identify  which protocol 
deviations are considered major before unblinding the study.  
PRIMARY ENDPOINT 
ANALYSIS  The primary efficacy endpoint will be the SPID MOVE  for [ADDRESS_375372]-T0.  The  muscle pain/soreness  intensity differences  will be 
calculated by [CONTACT_306623]-T 0 muscle pain/soreness  intensity  
score from the baseline muscle pain/soreness  intensity  score.  The 
weight given to each pain intensity difference  (PID) will be equal to 
the elapsed time since the previous evaluation.  
The mean SPID MOVE  for [ADDRESS_375373] -T0 will be compared between 
treatments using an analysis of covariance model with baseline muscle 
pain/soreness  score as a covariate . 
  
CONFIDENTIAL  Aponia Laboratories, Inc.  
 
Protocol Amendment 3 AP-007 Version: 02-Jul-[ADDRESS_375374] ............................................. 21	
9.1.1	 Study Drug ............................................................................................................ 21	
9.2	 Storage and Accountability ............................................................................................ 22	
9.3	 Study Drug Administration ............................................................................................ 22	
9.4	 Blinding ......................................................................................................................... 23	
9.5	 Study Drug Randomization ............................................................................................ 24	
9.6	 Compliance .................................................................................................................... 24	
9.7	 Study Restrictions .......................................................................................................... 24	
9.7.1	 Prior/Concomitant Medications ............................................................................ [ADDRESS_375375] Global Assessment ................................................................................... 26	
10.2	 Efficacy Assessments/Endpoints ................................................................................... 26	
10.2.1	 Primary Endpoint .................................................................................................. 26	
10.2.2	 Key Secondary Endpoints: .................................................................................... 26	
10.2.3	 Other Secondary Endpoints: ................................................................................. 26	
10.3	 Safety and Screening Assessments ................................................................................ 27	
10.3.1	 Medical History and Exercise History .................................................................. 27	
10.3.2	 Adverse Events ..................................................................................................... 27	
CONFIDENTIAL  Aponia Laboratories, Inc.  
 
Protocol Amendment 3 AP-007 Version: 02-Jul-2018 10 10.3.3	 Local Tolerability Assessments ............................................................................ 27	
10.3.4	 Clinical Laboratory Tests ...................................................................................... 28	
10.3.5	 Physical Examination ............................................................................................ 29	
10.3.6	 Vital Signs ............................................................................................................. 30	
10.3.7	 Electrocardiograms ............................................................................................... 30	
11	 STUDY PROCEDURES ...................................................................................................... 30	
11.1	 Screening Visit (Day -28 to Day -3) .............................................................................. 30	
11.2	 Exercise Visit (Day -1 or -2) .......................................................................................... 31	
11.3	 Treatment Period Visit (Days 1 to 3) ............................................................................. 33	
11.4	 Follow-up Telephone Call on Day 7 (¬±1 day) ............................................................... [ADDRESS_375376] Abnormalities .......... 41	
12.4	 Causality Assessments ................................................................................................... 41	
12.5	 Severity Assessments ..................................................................................................... 42	
12.6	 Serious Adverse Events ................................................................................................. 42	
12.7	 Pregnancy ....................................................................................................................... 43	
13	 DATA HANDLING ............................................................................................................. 43	
13.1	 Case Report Forms/Electronic Data Record .................................................................. [ADDRESS_375377]/Independent Ethics Committee .......................................... [ADDRESS_375378] of the Study ......................................................................................... 49	
15.3	 Informed Consent ........................................................................................................... 49	
15.4	 Confidentiality ............................................................................................................... 50	
15.5	 Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCPs .......... 50	
15.6	 Access to Records .......................................................................................................... 50	
15.7	 Retention of Records ...................................................................................................... 50	
15.8	 Monitoring, Quality Control and Quality Assurance ..................................................... 51	
CONFIDENTIAL  Aponia Laboratories, Inc.  
 
Protocol Amendment 3 AP-007 Version: 02-Jul-[ADDRESS_375379] OF TABLES  
Table 10-1	 Dermal Response and Numerical Equivalent ....................................................... 27	
 
CONFIDENTIAL  Aponia Laboratories, Inc.  
 
Protocol Amendment 3 AP-007 Version: 02-Jul-[ADDRESS_375380] 
LDH  lactate dehydrogenase 
MedDRA Medical Dictionary for Regulatory Activities 
NRS Numerical Rating Scale 
NSAID non-steroidal anti-inflammatory drug 
OTC  over-the-counter 
PI-NRS Pain Intensity Numerical Rating Scale 
PID pain intensity difference 
PPS Per Protocol Set 
SAE serious adverse event 
SOC system organ class 
SPID MOVE  sum of the time-weighted pain intensity differences from baseline with 
movement  
CONFIDENTIAL  Aponia Laboratories, Inc.  
 
Protocol Amendment 3 AP-007 Version: 02-Jul-[ADDRESS_375381] application of study drug 
TEAE treatment-emergent adverse event 
TOTPAR MOVE  total relief with movement 
US [LOCATION_002] 
WHO  World Health Organization 
WOCBP women of childbearing potential 
 
CONFIDENTIAL  Aponia Laboratories, Inc.  
 
Protocol Amendment 3 AP-007 Version: 02-Jul-2018 14 6 INTRODUCTION  
  
CBI
CB
I
CONFIDENTIAL  Aponia Laboratories, Inc.  
 
Protocol Amendment 3 AP-007 Version: 02-Jul-2018 15 
CBI
CONFIDENTIAL  Aponia Laboratories, Inc.  
 
Protocol Amendment 3 AP-007 Version: 02-Jul-2018 16 6.4 Indication 
The proposed indication for AP0302  is for  
CBI
CBI
CBI
CB
I
CONFIDENTIAL  Aponia Laboratories, Inc.  
 
Protocol Amendment 3 AP-007 Version: 02-Jul-2018 17 7 STUDY OBJECTIVE  
7.1 Objectives 
The primary objective of this study is to evaluate the efficacy of AP302 topi[INVESTIGATOR_34600]) 
 in DOMS of the elbow flexors in generally healthy subjects. 
The secondary objective is to evaluate the safety of AP0302 in DOMS of the elbow flexors 
in generally healthy subjects. 
8 OVERVIEW OF STUDY DESIGN  
This is a Phase 2/3, randomized, single-center, double-blind, vehicle-controlled, parallel-group study designed to determine the efficacy and safety of AP0302 (  
) for the treatment of muscle pain/soreness associated 
with DOMS.  Enough subjects will be screened to randomize 250 subjects.
  
Subjects will be screened up to 28 days prior to the Day 1.  After completing the informed consent process, the following procedures will be completed:  physical examination, medical 
history and concomitant medications collection, inclusion/exclusion criteria review, baseline 
laboratory testing, 12-lead electrocardiogram (ECG), pregnancy testing (females of child-bearing potential), drug and alcohol testing, and vital sign measurements. 
Subjects who meet initial inclusion/exclusion criteria will be scheduled to return to the research 
center to undergo an exercise regimen  
 
Between  hours following the end of the exercise regimen, subjects will return to the clinic to be evaluated for eligibility into the active treatment phase of the study. 
To qualify for randomization, subjects must report a  
CBI
CBI
CB
I
CBI
CBI
CBI
CBI
CBI
CBI
CBI
CONFIDENTIAL  Aponia Laboratories, Inc.  
 
Protocol Amendment 3 AP-007 Version: 02-Jul-[ADDRESS_375382] is an inpatient at the study site. Subjects will be awakened for IP dosing and efficacy 
assessments as necessary.   
Subjects will complete the following assessments at baseline: 
‚Ä¢ PI-NRS with movement 
‚Ä¢ Categorical Pain Rating score with movement (baseline only) 
‚Ä¢ Muscle Stiffness Numerical Rating Scale  (NRS) with movement  
The following assessments will be completed at , 
 hours post-initial IP dose and immediately prior to the 
subsequent doses of IP: 
‚Ä¢ PI-NRS with movement 
‚Ä¢ Muscle Stiffness NRS with movement  
The following assessment will be completed at  post-initial IP dose and 
immediately prior to a subsequent dose of IP if one occurs prior to : 
‚Ä¢ Relief from starting pain with movement on the Categorical Relief Rating Scale.   
At  post-initial dose (or prior to early termination, if applicable), the subject will 
complete a Subject Global Assessment to give their overall assessment of the IP. 
CBI
CBI
CBI
CBI
CBI
CBI
CBI
CBI
CBI
CONFIDENTIAL  Aponia Laboratories, Inc.  
 
Protocol Amendment 3 AP-007 Version: 02-Jul-[ADDRESS_375383] dose, and subjects will be discharged from the site at that time.  There will be a safety Follow-up Telephone Call on Day 7 (¬±1 day). 
8.[ADDRESS_375384] SELECTION 
8.1.1 Inclusion Criteria 
1. Generally healthy subjects aged 18 to 55 years (inclusive) at the time of signing the study informed consent form (ICF).  The subject is in good health, with no clinically significant medical conditions, as determined by [CONTACT_306624], physical examination, ECG, and screening laboratory results.   
2. Female subjects of childbearing potential (women who have experienced menarche and are not postmenopausal or permanently sterilized [by [CONTACT_306620], hysterectomy, or bilateral salpi[INVESTIGATOR_1656]]) will agree to use medically acceptable methods of contraception including but not limited to abstinence, birth control pi[INVESTIGATOR_255590], vaginal rings, diaphragm with vaginal spermicide, condom with vaginal spermicide, intrauterine device, and progestin implant or injection (used consistently for 3 months prior to study dosing) throughout the study and for [ADDRESS_375385] has a history of experiencing muscle pain/soreness after moderately strenuous exercise. 
4. Subject has a body mass index between [ADDRESS_375386] (IRB).  
6. Subject is willing and able to complete the standardized exercise regimen.  
Post-Exercise:  
7.
CBI
CBI
CONFIDENTIAL  Aponia Laboratories, Inc.  
 
Protocol Amendment 3 AP-007 Version: 02-Jul-2018 20 ‚Äúmoderate‚Äù on a Categorical Pain Rating Scale using the words ‚Äúnone‚Äù ‚Äúmild,‚Äù ‚Äúmoderate,‚Äù 
or ‚Äúsevere.‚Äù  
8.1.[ADDRESS_375387] a job or hobby [CONTACT_306625] (eg, rock climbers, movers, construction workers).  
3. Subjects with a history of surgery, significant trauma, significant musculoskeletal pathology, or significant nervous system pathology in the neck or in the non-dominant arm or shoulder 
that is likely to be exacerbated by [CONTACT_306622], in the opi[INVESTIGATOR_871]. 
4. Subjects with any condition, in the investigator‚Äôs judgment, that may interfere with local 
tolerability assessments in the area of study drug application, including recently applied tattoos. 
5. History of any muscle disorder (eg, statin myopathy or any muscular dystrophy), neuropathy, fibromyalgia, rhabdomyolysis, or chronic fatigue syndrome. 
6. Presence of another painful physical condition that, in the opi[INVESTIGATOR_871], may confound study assessments. 
7. Any contraindication to the use of ibuprofen, or any nonsteroidal anti-inflammatory drug (NSAID) or cyclooxygenase-2 inhibitor, or aspi[INVESTIGATOR_248], including any history of asthma or recent history of gastritis or gastrointestinal bleeding. 
8. Presence of an allergy or intolerance to any NSAID or aspi[INVESTIGATOR_306611]. 
9. Presence of a latex allergy (customized armband components contain latex).  
10. Any skin condition that could potentially interfere with absorption of drug (eg, keloid, rash, dermatitis). 
11. Have received chronic opi[INVESTIGATOR_306612] [ADDRESS_375388] received an opi[INVESTIGATOR_306610] 30 days prior to Day 1.  
13. Routine use (defined as 3 out of 7 days per week) of any analgesic drug ( OTC  or 
prescription).  
CONFIDENTIAL  Aponia Laboratories, Inc.  
 
Protocol Amendment 3 AP-007 Version: 02-Jul-2018 21 14. Consumption of any medication (prescription or OTC  medications, vitamins, minerals, and 
dietary supplements) within 2 weeks prior to Day 1.  Exception: continuing hormonal 
contraception and hormone replacement therapy is allowed.   
15. Any history of drug or alcohol abuse (according to the investigator‚Äôs judgment) in the prior 
[ADDRESS_375389]‚Äôs ability to safely complete all study procedures (including the exercise regimen) or 
might interfere with the efficacy results of the study. 
8.[ADDRESS_375390] Identification 
Subjects will be identified by [CONTACT_306626].  
8.3 Replacement of Subjects 
Subjects who discontinue prior to completion of the study may be replaced at the sponsor‚Äôs discretion. 
[ADDRESS_375391] 
9.1.1 Study Drug 
CBI
CONFIDENTIAL  Aponia Laboratories, Inc.  
 
Protocol Amendment 3 AP-007 Version: 02-Jul-2018 22 9.2 Storage and Accountability 
9.3 Study Drug Administration 
CBI
CBI
CBI
CONFIDENTIAL  Aponia Laboratories, Inc.  
 
Protocol Amendment 3 AP-007 Version: 02-Jul-[ADDRESS_375392]‚Äôs condition requires knowledge of the treatment assignment.  Any such cases will be clearly justified and explained in a note to file.  The investigator will notify the Aponia medical monitor immediately in the event of the situation.   
CBI
CONFIDENTIAL  Aponia Laboratories, Inc.  
 
Protocol Amendment 3 AP-007 Version: 02-Jul-2018 24 9.5 Study Drug Randomization 
Subjects will be required to meet the eligibility for study drug application on Day 1 (see 
Section 11.3), prior to assignment of the study drug box.  Study drug boxes will be assigned by [CONTACT_306627].   
9.[ADDRESS_375393] dose. 
9.7 Study Restrictions 
9.7.1 Prior/Concomitant Medications  
The following restrictions on prior/concomitant medications will apply: 
‚Ä¢ May not have received chronic opi[INVESTIGATOR_306612] 15 morphine 
equivalents units per day for greater than 3 out of 7 days per week in any 1-month period 
within 12 months prior to Day 1.   
‚Ä¢ May not have received an opi[INVESTIGATOR_306610] 30 days prior to Day 1. 
‚Ä¢ Must not routinely use (defined as 3 out of 7 days per week) any analgesic drug (OTC or prescription).  
‚Ä¢ Must not have consumed of any medication (prescription or OTC  medications, vitamins, 
minerals, and dietary supplements) within 2 weeks prior to randomization.  Exception: continuing hormonal contraception and hormone replacement therapy is allowed.   
Any medication, including supplements, vitamins, and non-medicinal therapi[INVESTIGATOR_306613] 30 days prior to the Screening Visit through the Follow-up Telephone Call will be recorded in the case report form (CRF). 
9.7.2 Non-medicinal Therapi[INVESTIGATOR_306614], the 
application of heat, ice or other non-medicinal therapi[INVESTIGATOR_306615]-dominant arm are 
prohibited. 
9.7.3 Activity Restriction 
CBI
CONFIDENTIAL  Aponia Laboratories, Inc.  
 
Protocol Amendment 3 AP-007 Version: 02-Jul-[ADDRESS_375394] Rating Scales 
Subjects will receive training on how to use rating scales to report muscle pain/soreness, muscle 
stiffness and relief from starting pain (see separate study reference document and subject rating 
scales presented in Appendix 2).   
10.1.1 Pain Intensity NRS 
Subjects will rate muscle pain/soreness with movement  
10.1.2 Categorical Pain Rating Scale for Eligibility 
At baseline only, subjects will also report muscle pain/soreness with movement on the 
Categorical Pain Rating Scale: ‚Äúnone,‚Äù ‚Äúmild,‚Äù ‚Äúmoderate‚Äù or ‚Äúsevere.‚Äù  
. 
10.1.3 Muscl e Stiffness NRS  
Subjects will rate muscle stiffness with movement using an 11-point Muscle Stiffness NRS anchored at zero (0) for no stiffness and [ADDRESS_375395] possible stiffness. 
10.1.4 Categorical Relief Rating Scale 
Subjects will rate relief from starting pain with movement using a 5-point categorical relief scale : 
‚Äúno relief,‚Äù ‚Äúa little relief,‚Äù ‚Äúsome relief,‚Äù ‚Äúa lot of relief,‚Äù or ‚Äúcomplete relief.‚Äù 
CBI
CBI
CBI
CBI
CBI
CBI
CONFIDENTIAL  Aponia Laboratories, Inc.  
 
Protocol Amendment 3 AP-007 Version: 02-Jul-[ADDRESS_375396] Global Assessment  
Subjects will rate their global assessment by [CONTACT_16134]:   
Overall, how would you rate the investigational product you received? 
‚ñ° Poor (0) 
‚ñ° Fair (1) 
‚ñ° Good (2) ‚ñ° Very Good (3) ‚ñ° Excellent (4) 
10.2 Efficacy Assessments/Endpoints 
10.2.1 Primary Endpoint 
The primary endpoint is the sum of the time-weighted pain intensity differences (PI[INVESTIGATOR_29721]) from 
baseline with movement (SPID
MOVE ) over 0-[ADDRESS_375397]-T 0 (SPID MOVE 0-24 hours). Muscle 
pain/soreness with movement will be scored using the PI-NRS described in Section 10.1.[ADDRESS_375398]-T 0 pain score from the baseline (prior to T 0) pain score.  The weight given 
to each PID will be equal to the elapsed time since the previous evaluation.  
10.2.2 Key Secondary Endpoints: 
‚Ä¢ SPID MOVE  over the following intervals: 0-6, 6-12, 0-12, 12-24, 24-36, 0-36, 24-48, 36-48, 
and 0-[ADDRESS_375399]-T 0. 
10.2.3 Other Secondary Endpoints: 
‚Ä¢ Sum of time-weighted differences from baseline in muscle stiffness with movement 
(SSID MOVE ) over the following intervals: 0-6, 6-12, 0-12, 12-24, 0-24, 0-36, 24-48, and 
0-[ADDRESS_375400]-T 0. 
‚Ä¢ Total relief with movement (TOTPAR MOVE ) over 0-[ADDRESS_375401]-T 0. 
‚Ä¢ Subject‚Äôs global assessment of study medication assessed at approximately [ADDRESS_375402]-T 0 (or upon early termination, if applicable).  
CONFIDENTIAL  Aponia Laboratories, Inc.  
 
Protocol Amendment 3 AP-007 Version: 02-Jul-[ADDRESS_375403] medical or surgical procedures as well as previous and current 
co-existent diseases.  It should include relevant medical history for the following body systems: 
head, eyes, ears, nose, and throat (HEENT ); respi[INVESTIGATOR_696]; cardiovascular; gastrointestinal; 
endocrine; hematological; dermatological; genital-urinary (including reproductive history); neurological; musculoskeletal; psychological/psychiatric; and any other history of medical significance.  Changes in health occurring between the Screening Visit and the Treatment Period Visit , prior to the first dose of study medication, will be captured as medical history. 
At the Screening Visit and Exercise Visit, subjects will be questioned about their exercise history to verify continued eligibility.  Subjects who have worked out or exercised the upper extremities 
with weights or gym equipment during the past 3 months will not be eligible for the study. 
10.3.2 Adverse Events 
Adverse events will be defined, described, recorded, and reported according to Section 12. 10.3.3 Local Tolerability Assessments 
 
CBI
CBI
CONFIDENTIAL  Aponia Laboratories, Inc.  
 
Protocol Amendment 3 AP-007 Version: 02-Jul-2018 28 10.3.4 Clinical Laboratory Tests 
The subjects are not required to be in the fasted state for the clinical laboratory testing.  
Laboratory testing (multiphasic chemistry panel, hematology panel, coagulation, and urinalysis) will be performed at the Screening Visit and on Day [ADDRESS_375404] dose.  Urine dipsticks will be used for the urine drug screens. 
In women of childbearing potential (WOCBP; women who have experienced menarche and are 
not postmenopausal or permanently sterilized [by [CONTACT_306620], hysterectomy, or bilateral salpi[INVESTIGATOR_1656]]), urine pregnancy tests will be performed at the Screening Visit, Exercise Visit and on Day 1 (pre-dose).  
: 
CBI
CBI
CONFIDENTIAL  Aponia Laboratories, Inc.  
 
Protocol Amendment 3 AP-007 Version: 02-Jul-2018 29  Physical Examination 
A complete physical examination will be conducted during the Screening Visit and on Day 3 at 
54 hours and will include assessment of the following: HEENT ; neck (including an examination 
of the thyroid); heart; lungs; abdomen (including an examination of the liver and spleen); lymph nodes; extremities; nervous system; and skin.   
CBI
CBI
CBI
CONFIDENTIAL  Aponia Laboratories, Inc.  
 
Protocol Amendment 3 AP-007 Version: 02-Jul-2018 30 An abbreviated, symptom-directed physical examination will be performed at the Exercise Visit 
on Day -1 or -2.  The abbreviated, symptom-directed physical examination is to be performed at 
the Exercise Visit to re-assess any abnormal clinically significant findings identified at the 
screening exam and/or to assess any current symptoms at the time of the symptom-directed exam.  If there are no abnormal clinically significant findings at the screening visit AND no current symptoms, a symptom-directed examination is not required. 
10.3.6 Vital Signs 
Vital signs (blood pressure, heart rate, temperature, and respi[INVESTIGATOR_697]) will be recorded at the 
Screening Visit, at the Exercise Visit (Day -1 or 2), on Day 1 pre-dose, and Day 3 at 54 hours (or at early termination, if applicable).  Measurements are to be obtained after the subject has been seated and resting quietly for at least [ADDRESS_375405] be reviewed for clinically 
meaningful deviations from normal prior to exercise. 
11 STUDY PROCEDURES  
An overview of the study assessments and procedures is presented in the Schedule of Assessments, Appendix 1. 
11.1 Screening Visit (Day -28 to Day -3) 
The investigator or designated qualified study personnel will perform the following assessments 
at the Screening Visit:  
‚Ä¢ Obtain written informed consent. 
‚Ä¢ Verify eligibility via inclusion and exclusion criteria.  
‚Ä¢ Record demographics. 
CBI
CONFIDENTIAL  Aponia Laboratories, Inc.  
 
Protocol Amendment 3 AP-007 Version: 02-Jul-2018 31 ‚Ä¢ Obtain medical history and exercise history.  Subjects who have exercised the upper 
extremities with weights or gym equipment within the prior 3 months will not be eligible 
for the study. 
‚Ä¢ Height and weight will be recorded. 
‚Ä¢ Record prior/current medications and non-medicinal therapi[INVESTIGATOR_014]. 
‚Ä¢ Perform a physical examination,  
 (as described in Section 10.3.5). 
‚Ä¢ Record vital sign measurements (blood pressure, heart rate, temperature, and respi[INVESTIGATOR_697]) after subject has been in a seated position and resting quietly for at least 5 minutes.   
‚Ä¢ Perform 12-lead ECG with the subject in a supi[INVESTIGATOR_306616] [ADDRESS_375406] be reviewed for clinically meaningful deviations 
from normal prior to exercise. 
‚Ä¢ Obtain screening laboratory tests as follows: 
o Obtain blood and urine for screening laboratory tests (multiphasic chemistry, hematology, coagulation, and urinalysis).  
o Obtain urine for urine drug screen.  
o Perform alcohol breath test. 
o Obtain sample for urine pregnancy test for WOCBP. 
All information and clinical findings will be recorded in the appropriate sections of the CRFs.  
The investigator will make the final determination of whether a subject is eligible for the study.  
All subjects screened will be documented on the Screening Log.  Specific reasons for excluding any potential subject will be recorded. 
11.2 Exercise Visit (Day -1 or -2) 
Subjects will return to the research unit on the day of exercise.   
 
The following assessments and procedures will be performed prior to the exercise: 
‚Ä¢ Eligibility will be re-assessed. 
CBI
CBI
CBI
CBI
CBI
CONFIDENTIAL  Aponia Laboratories, Inc.  
 
Protocol Amendment 3 AP-007 Version: 02-Jul-2018 32 ‚Ä¢ Update medical history.  Changes in health between the Screening Visit and the Exercise 
Visit will be captured as medical history. 
‚Ä¢ Record prior/current medications and non-medicinal therapi[INVESTIGATOR_014]. 
‚Ä¢ An abbreviated, symptom-directed physical examination will be performed, if indicated. 
‚Ä¢ Vitals signs (blood pressure, heart rate, temperature, and respi[INVESTIGATOR_697]) will be collected after the subject has been seated for at least 5 minutes.  
‚Ä¢ Obtain urine and perform urine drug screen.  Results should be reviewed prior to exercise. 
‚Ä¢ Obtain urine sample and perform urine pregnancy test in WOCBP.  Results should be 
reviewed prior to exercise. 
‚Ä¢ Perform the alcohol breath test.  Results should be reviewed prior to exercise.  
CBI
CBI
CONFIDENTIAL  Aponia Laboratories, Inc.  
 
Protocol Amendment 3 AP-007 Version: 02-Jul-2018 33 11.3 Treatment Period Visit (Days 1 to 3) 
 
.  The following assessments and procedures will be performed to determine 
eligibility: 
‚Ä¢ Eligibility will be re-assessed. 
‚Ä¢ Update medical history.  Changes in health between the Screening Visit until the 
Treatment Period Visit, prior to the first dose of study medication, will be captured as 
medical history. 
‚Ä¢ Review prior/current medications and non-medicinal therapi[INVESTIGATOR_014]. 
‚Ä¢ Vitals signs (blood pressure, heart rate, temperature, and respi[INVESTIGATOR_697]) will be 
collected after the subject has been seated for at least 5 minutes.  
‚Ä¢ Obtain urine for a urine drug screen.  Results should be reviewed prior to treatment with IP. 
‚Ä¢ Perform the alcohol breath test.  Results should be reviewed prior to treatment with IP. 
‚Ä¢ Obtain sample for urine pregnancy test in WOCBP.  Results should be reviewed prior to treatment with IP. 
CBI
CBI
CBI
CONFIDENTIAL  Aponia Laboratories, Inc.  
 
Protocol Amendment 3 AP-007 Version: 02-Jul-2018 34 
CBI
CONFIDENTIAL  Aponia Laboratories, Inc.  
 
Protocol Amendment 3 AP-007 Version: 02-Jul-2018 35 ‚Ä¢ The following assessments are to be completed at , 
 post first dose of IP and immediately 
prior to the subsequent doses of IP: 
o Muscle pain/soreness with movement on the PI-NRS  
o Muscle Stiffness with movement on the Muscle Stiffness NRS  
CBI
CBI
CBI
CONFIDENTIAL  Aponia Laboratories, Inc.  
 
Protocol Amendment 3 AP-007 Version: 02-Jul-2018 36 ‚Ä¢ The following assessment is to be completed at  post first dose of 
IP and immediately prior to a subsequent dose of IP, if one occurs prior to  
o Relief from starting pain with movement on the Categorical Relief Rating 
Scale  
‚Ä¢  
 
. 
‚Ä¢ At approximately  post-T 0, the Subject Global Assessment of IP will be recorded 
in addition to the  NRS assessments. 
‚Ä¢  
‚Ä¢ Record any AEs and any concomitant medications or non-medicinal therapi[INVESTIGATOR_306617]. 
On Day 3, at approximately  post-T
0, the following assessments and procedures will be 
performed: 
‚Ä¢  
 
‚Ä¢ Perform a physical examination,  
). 
‚Ä¢ Record vital sign measurements (blood pressure, heart rate, temperature, and respi[INVESTIGATOR_862]) after subject has been in a seated position and resting quietly for at least 5 minutes.   
‚Ä¢ Perform 12-lead ECG with the subject in a supi[INVESTIGATOR_306616] 10 minutes. 
‚Ä¢ Obtain laboratory tests as follows: 
o Obtain blood and urine for laboratory tests (multiphasic chemistry, hematology, 
coagulation, and urinalysis).  
‚Ä¢ Any AEs and concomitant medications or non-drug therapi[INVESTIGATOR_79005]. 
After these final assessments have been performed, the subject can be discharged from the site. 
CBI
CBI
CBI
CBI
CBI
CBI
CBI
CBI
CBI
CBI
CONFIDENTIAL  Aponia Laboratories, Inc.  
 
Protocol Amendment 3 AP-007 Version: 02-Jul-2018 37 11.4 Follow-up Telephone Call on Day 7 (¬±1 day) 
Subjects will be called on Day 7 (¬±1 day) and the following assessments will be performed: 
‚Ä¢ Record prior/current medications and non-medicinal therapi[INVESTIGATOR_014]. 
‚Ä¢ Record any AEs.  
Each AE will be followed until it resolves, until the investigator assesses the subject‚Äôs status to 
have returned to baseline, or until the investigator feels that the event is stable and chronic. 
11.5 Order of Procedures 
CBI
CBI
CBI
CONFIDENTIAL  Aponia Laboratories, Inc.  
 
Protocol Amendment 3 AP-007 Version: 02-Jul-2018 38 11.6 Allowable Windows 
11.7 Early Termination Assessments 
Subjects who discontinue early from the study after receiving IP, will undergo the following 
assessments and procedures: 
‚Ä¢ The subject‚Äôs global assessment of IP will be recorded (if termination is prior to this 
48-hour assessment). 
‚Ä¢ Perform a physical examination, including a neuromuscular and strength assessment of 
the upper extremities (as described in Section 10.3.5). 
‚Ä¢ Record vital sign measurements (blood pressure, heart rate, temperature, and respi[INVESTIGATOR_862]) after subject has been in a seated position and resting quietly for at least 5 minutes.   
CBI
CBI
CBI
CONFIDENTIAL  Aponia Laboratories, Inc.  
 
Protocol Amendment 3 AP-007 Version: 02-Jul-2018 39 ‚Ä¢ Perform 12-lead ECG with the subject in a supi[INVESTIGATOR_306616] 10 minutes. 
‚Ä¢ Obtain laboratory tests as follows: 
o Obtain blood and urine for laboratory tests (multiphasic chemistry, hematology, 
coagulation, and urinalysis).  
‚Ä¢ Any AEs and concomitant medications or non-drug therapi[INVESTIGATOR_79005]. 
11.[ADDRESS_375407] may be removed from the study for medical or administrative reasons such as the following: 
‚Ä¢ AE 
‚Ä¢ Lack of efficacy 
‚Ä¢ Noncompliance with study drug 
‚Ä¢ Protocol deviation 
‚Ä¢ Subject withdrawal 
‚Ä¢ Lost to follow-up 
‚Ä¢ Physician decision 
‚Ä¢ Other reasons as determined by [CONTACT_8893] 
11.[ADDRESS_375408] is estimated to be as follows: 
CBI
CBI
CONFIDENTIAL  Aponia Laboratories, Inc.  
 
Protocol Amendment 3 AP-007 Version: 02-Jul-[ADDRESS_375409] a 
causal relationship with this treatment.  An AE can therefore be any unfavorable and unintended 
sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. 
A TEAE is defined as an AE that is new or worsened in severity after the first dose of study 
drug. 
12.[ADDRESS_375410] dose of study drug; the investigator should record any SAEs from the time 
of signing the ICF until [ADDRESS_375411] be reported in the CRF. 
Each AE will be judged as to the relationship to study medication (as defined in Section 12.4), 
the severity (as defined in Section 12.5), and whether it meets the criteria for an SAE (as defined in Section 12.6). 
CONFIDENTIAL  Aponia Laboratories, Inc.  
 
Protocol Amendment 3 AP-007 Version: 02-Jul-[ADDRESS_375412]‚Äôs 
status to have returned to normal, or until the investigator feels that the event is stable and chronic.  
12.3  
12.4 Causality Assessments 
Each AE will be judged as to whether it is related, possibly related, or unrelated to the IP.  The following definitions will be used for these causality assessments. 
Related:  This causal relationship is assigned when the AE: 
‚Ä¢ starts a reasonable time after study drug administration, 
‚Ä¢ stops/improves when study drug has been stopped, 
‚Ä¢ can reasonably be explained by [CONTACT_200503], and 
‚Ä¢ cannot be reasonably explained by [CONTACT_423]‚Äôs clinical state. 
Possibly Related:  This causal relationship is assigned when the AE: 
‚Ä¢ starts a reasonable time after study drug administration, but 
‚Ä¢ could have been produced by [CONTACT_423]‚Äôs clinical state or other modes of therapy administered to the subject. 
CBI
CBI
CONFIDENTIAL  Aponia Laboratories, Inc.  
 
Protocol Amendment 3 AP-007 Version: 02-Jul-[ADDRESS_375413] parties, except for authorized representatives of Aponia Laboratories, Inc. or appropriate regulatory authorities, without written permission from Aponia Laboratories, Inc. 
The investigator has ultimate responsibility for the collection and reporting of all clinical, safety 
and laboratory data entered on the CRFs and data collection forms (source documents) and ensuring that they are accurate, authentic / original, attributable, complete, consistent, legible, timely (contemporaneous), enduring and available when required.  The CRFs must be signed by [CONTACT_306628].  Any corrections to entries made in the CRFs, source documents must be dated, initialed and explained (if necessary) and should not obscure the original entry.  
13.2 Clinical Database 
Creation and validation of the clinical database and entry and management of data will be conducted in accordance with Title 21 of the Code of Federal Regulations Part 11 and the guidance for industry on computerized systems used in clinical trials.  Methods used to ensure the quality and integrity of the data will be documented in the data management plan. 
14 STATISTICS  
Detailed methodology for summary and statistical analyses of the data collected in this study will be documented in a Statistical Analysis Plan, which will be signed off prior to the database lock.  
14.1 Analysis Populations 
The following populations will be utilized: 
‚Ä¢ Safety Population: all subjects who receive at least 1 dose of study drug.  The demographic, baseline characteristics, and safety data summaries will be based on the Safety Population. 
‚Ä¢ Full Analysis Set (FAS): all subjects who are randomized, receive at least [ADDRESS_375414]-baseline efficacy assessment. 
‚Ä¢ Per Protocol Set  (PPS): all subjects in the FAS without a major protocol deviation.  The 
sponsor will identify which protocol deviations are considered major before unblinding the study.  
CONFIDENTIAL  Aponia Laboratories, Inc.  
Protocol Amendment 3 AP-007 Versio n: 02-Jul-[ADDRESS_375415] available randomization number.  Assignment to active and vehicle control will be in a 1:1 ratio. 
14.3 Sample Size Determination 
A sufficient number of generally healthy subjects of either gender will be enrolled to obtain 250 randomized subjects.  The sample size of 250 subjects (125 for each of the treatment group) 
 
 
14.[ADDRESS_375416] dose of study drug is considered 
time 0, T
0.  Efficacy parameters will be analyzed using both the FAS and the PPS. 
14.4.1 Primary Efficacy Endpoint and Analysis 
The primary efficacy outcome is the sum of the time-weighted differences from baseline in 
muscle pain/soreness with movement (SPID MOVE ) over 0-[ADDRESS_375417]-T 0 (SPID MOVE  0-24h), that 
is the area under the differences from baseline pain/soreness intensity difference curve. 
The PI[INVESTIGATOR_306618] A to time point B will be calculated using the 
trapezoid rule by [CONTACT_306623]-T 0 pain score with movement from the pain score with 
movement at time point T i as follows: 
‚Ä¢PID with movement at time point i (PID MOVE  i) = NRS score with movement at time point
i ‚Äì NRS score with movement  at baseline.
‚Ä¢Mean of adjacent pain intensity differences M MOVEi  = (PID MOVE i  +  PID MOVE  i+1) / 2
‚Ä¢The weight given to each M MOVE  i score (W i) = elapsed time to the next  evaluation (ti+1 ‚Äì
ti).
‚Ä¢SPID MOVE A-B hr = ùëä!!!!
!!!  ùëÄ!"#$%   where i refers to each NRS scheduled assessment 
time point between A and B (not including B). 
Thus, SPID MOVE  0-24h =ùëä!ùëÄ!"#$ !!"
!!! , where i refers to each NRS scheduled assessment time 
point between baseline and 24 hours. 
 
 
CBI
CONFIDENTIAL  Aponia Laboratories, Inc.  
 
Protocol Amendment 3 AP-007 Version: 02-Jul-2018 46 The general formula for computing SPID between any two time points a and b is as follows:  
ùëÜùëÉùêºùê∑ !!!= ùë°!!!‚àíùë°!ùëÉùêºùê∑ !!!+ùëÉùêºùê∑ !
2!!!
!!! 
Where i refers to each scheduled assessment time point between a and b hours post 
baseline, t i is the ith time point and PID i is the pain intensity difference at time i 
The mean SPID MOVE  for 0-[ADDRESS_375418]-T 0 will be compared between the 2 treatment groups 
using an analysis of covariance (ANCOVA) model with baseline pain/soreness score as a 
covariate.  
14.4.2 Key Secondary Efficacy Endpoints and Analyses 
Following the similar formula mentioned in the previous section, the following SPID MOVE  for the 
different time intervals will be estimated and compared for the 2 treatment groups using the same 
ANCOVA model. 
‚Ä¢ SPID MOVE  over the following intervals: 0-6, 6-12, 0-12, 12-24, 24-36, 0-36, 24-28, 36-48, 
and 0-[ADDRESS_375419]-T 0 will be compared between the 2 treatment groups 
(active versus vehicle) using an ANOCVA model with the baseline pain/soreness score as the covariate. 
14.4.3 Other Secondary Analyses 
The following other secondary endpoints for different time intervals will be compared between 
the 2 treatment groups using an ANCOVA model with the baseline pain/soreness score as the covariate. 
‚Ä¢ SSID MOVE  over the following intervals: 0-6, 6-12, 0-12, 12-24, 0-24, 0-36, 24-48, and 
0-[ADDRESS_375420]-T 0 will be compared between the 2 treatment groups (active versus 
vehicle) using an ANOCVA model with the baseline muscle stiffness score as the covariate.
 
‚Ä¢ TOTPAR MOVE  over 0-[ADDRESS_375421]-T 0.  An ANOVA model will be used for these efficacy 
endpoints. 
TOTPAR MOVE  A-B hr = ùë∑ùëπ ùíäùë©!ùüè
ùíä!ùë®  ùëØ    where i refers to each pain relief scheduled 
assessment time point between A and B (not including B).      :  
CONFIDENTIAL  Aponia Laboratories, Inc.  
 
Protocol Amendment 3 AP-007 Version: 02-Jul-[ADDRESS_375422]‚Äôs global assessment of efficacy will be assessed at approximately [ADDRESS_375423]-T 0 
(or upon early termination if the subject withdraws prior to the 48-hour assessment).  The 
distribution of 5 categories (poor, fair, good, very good, or excellent) will be compared between 
the 2 treatments (active versus vehicle) using the Chi-Squared test.  In addition, the 5 categories will be dichotomized into 2 categories (good/very good/excellent versus poor/fair).  The proportion of good, very good, and excellent ratings will be calculated for each treatment.  This proportion will be compared between the 2 treatments (active versus vehicle) using the Fisher‚Äôs Exact test. 
14.[ADDRESS_375424] deviation will be summarized for continuous variables.  Frequency distributions will be 
summarized for categorical variables.  Since all subjects will receive vehicle on the dominant arm in addition to blinded study drug on the non-dominant arm, some subjects will receive both active and vehicle treatments. All safety-related data will be summarized as an overall group except AEs  related to the area of application. 
Adverse events will be coded using the Medical Dictionary for Regulatory Activities ( MedDRA) 
version 19.1 (or higher).  For summary tables, AEs coded to the same preferred term will be counted only once within a given subject.  If an AE was recorded on multiple occasions in the 
same treatment period, only the highest severity and the highest degree of relationship to the 
study drug will be presented.  If [ADDRESS_375425] dose of study drug.  Adverse events will be summarized by [CONTACT_9313] (SOC), and preferred term.  Summaries will be prepared for all AEs, treatment-related AEs, and SAEs.  The 
AE summary will also be presented with a breakdown by [CONTACT_926].  Adverse events that are 
specific to the arm, such as application site reactions, will be summarized by [CONTACT_3148] (active versus vehicle).  
Changes from baseline in chemistry, hematology, coagulation, and urinalysis parameters will be 
summarized descriptively.  Laboratory results will be classified as low, normal, or high according 
to the laboratory-supplied reference ranges.  Shift tables describing out-of-range shifts from 
CONFIDENTIAL  Aponia Laboratories, Inc.  
 
Protocol Amendment 3 AP-007 Version: 02-Jul-2018 48 baseline (in frequency counts) will be created and presented by [CONTACT_3148].  All laboratory results 
will be listed. 
The results of physical examinations will be summarized by [CONTACT_306629], and if abnormal whether it is clinically significant or 
non-clinically significant.  A listing of physical examination results will be presented by [CONTACT_306630].  
Results of the ECGs will be presented as normal, abnormal (clinically significant), and abnormal 
(not clinically significant).  These results will be listed by [CONTACT_306631].  
Vital signs will be listed by [CONTACT_306632].  
Prior and concomitant medications will be coded using the World Health Organization ( WHO) 
Drug Dictionary and summarized  descriptively.  Prior medications are defined as any medications 
started prior to the day of the first dose of study drug.  Concomitant medications  are defined as any 
medications taken on the day of or after the first dose of study drug.  Prior and concomitant 
medications  will be coded usi ng the WHO Drug Dictionary version of September [ADDRESS_375426] w ill be counted only 
once for a given prior or concomitant treatment.  Prior and concomitant non -medicinal therapi[INVESTIGATOR_014] 
(non- drug treatments) will be coded using MedDRA and then summarized in a similar manner as 
prior and concomitant medications.  
 
14.[ADDRESS_375427] and will be summarized descriptively.  Medical history will be coded using MedDRA and summarized by [CONTACT_9315].   
CBI
CBI
CONFIDENTIAL  Aponia Laboratories, Inc.  
 
Protocol Amendment 3 AP-007 Version: 02-Jul-[ADDRESS_375428]/Independent Ethics Committee 
It is the responsibility of the investigator to have prospective approval of the study protocol, 
protocol amendments, informed consent documents, and other relevant documents, eg, 
recruitment advertisements, if applicable, from the IRB/IEC.  All correspondence with the 
IRB/IEC should be retained in the Investigator File.  Copi[INVESTIGATOR_1099]/IEC approvals should be forwarded to Aponia Laboratories, Inc. 
Any changes to the protocol will require approval of the sponsor, in writing, and the IRB/IEC 
prior to implementation.  The only circumstance in which an amendment may be initiated prior to IRB/IEC approval is where the change is necessary to eliminate apparent immediate hazards to the subjects.  In that event, the investigator must notify the IRB/IEC and Aponia Laboratories, Inc. in writing immediately after the implementation. 
15.[ADDRESS_375429] of the Study 
The study will be conducted in accordance with the protocol, the FDA, applicable local regulatory requirements and laws, as well as the general principles set forth in the International Ethical Guidelines for Biomedical Research Involving Human Subjects (Council for International Organizations of Medical Sciences 2002), Guidelines for Good Clinical Practices (GCPs) (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use [ICH] 1996), and the Declaration of Helsinki (World Medical 
Association 2008).  The rights, safety, and well-being of the study subjects are the most 
important consideration and prevail over the interests of science and society.  All personnel involved in the conduct of this study must be qualified by [CONTACT_8640], training, and experience to perform their assigned responsibilities.  
15.[ADDRESS_375430]'s legal representative before any study-specific activity is performed.  The investigator must ensure that each study subject, or his/her legal 
representative, is fully informed about the nature and objectives of the study and possible risks 
associated with participation.  The subject will be given ample time to review the ICF and the opportunity to discuss any questions before making a decision about participation in this study.  The process of informed consent will be documented in the subject‚Äôs source data.  The investigator will retain the original of each subject's signed consent document and a signed copy will be provided to the subject. 
CONFIDENTIAL  Aponia Laboratories, Inc.  
 
Protocol Amendment 3 AP-007 Version: 02-Jul-[ADDRESS_375431] be approved by [CONTACT_28150]/IEC and Aponia Laboratories, Inc. before use. 
15.[ADDRESS_375432] personal data. 
15.5 Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCPs 
In the event of any prohibition or restriction imposed (ie, clinical hold) by [CONTACT_306633], or if the investigator is aware of any new information which might influence the evaluation of the benefits and risks of the investigational product, Aponia Laboratories, Inc. should be informed immediately.   
In addition, the investigator will inform Aponia Laboratories, Inc. immediately of any urgent 
safety measures taken by [CONTACT_1205], and of any serious breaches of this protocol or of ICH GCPs that the investigator 
becomes aware of. 
15.6 Access to Records 
The investigator and study personnel will permit study-related monitoring, audits, IRB/IEC 
review, and regulatory inspections by [CONTACT_60282]. 
15.7 Retention of Records 
To enable evaluations and/or audits from regulatory authorities or Aponia Laboratories, Inc., the 
investigator agrees to keep records, including the identity of all participating subjects (sufficient 
information to link records, eg, CRFs and hospi[INVESTIGATOR_1097]), all original signed informed consent 
documents, copi[INVESTIGATOR_4600], safety reporting forms, source documents, and detailed records of treatment disposition, and adequate documentation of relevant correspondence (eg, letters, meeting minutes, telephone calls reports).   
CONFIDENTIAL  Aponia Laboratories, Inc.  
 
Protocol Amendment 3 AP-007 Version: 02-Jul-[ADDRESS_375433] arrange for retention of study records at the site for 2 years after the 
AP0302 5% New Drug Application is approved or the Investigational New Drug application is 
withdrawn, as required by [CONTACT_1260].  If the investigator becomes unable for any reason to continue to retain study records for the required period (eg, retirement, relocation), Aponia 
Laboratories, Inc. should be immediately notified.  The study records must be transferred to a 
designee acceptable to Aponia Laboratories, Inc., such as another investigator, another institution, or to an independent third party arranged by [CONTACT_306634], Inc.     
The investigator must obtain Aponia's written permission before disposing of any records, even 
if retention requirements have been met. 
15.[ADDRESS_375434] periodic monitoring visits to ensure that the protocol and GCPs are being followed.  The monitor will ensure there are 
no deviations to the informed consent process for all screened subjects.  Source data will be 
reviewed to confirm that there are no deviations to the study protocol and data recorded on CRFs are accurate.  The monitor will ensure the following:  that essential documents are maintained and IRB approval current; that the study drug is stored appropriately; that drug accountability records are complete and accurate; and that the site‚Äôs resources remain adequate for the conduct of the trial.  The investigator and institution will allow Aponia Laboratories, Inc. monitors or its agents and appropriate regulatory authorities direct access to source documents and all study records to perform this verification. 
The study site may be subject to review by [CONTACT_1201]/IEC, to quality assurance audits performed 
by [CONTACT_306634], Inc., or companies working with or on behalf of Aponia Laboratories, Inc., and/or to inspection by [CONTACT_4708]. 
It is important that the investigator(s) and their relevant personnel are available during the 
monitoring visits and possible audits or inspections and that sufficient time is devoted to the process. 
15.9 Sponsor Discontinuation Criteria 
Premature termination of this study may occur because of a regulatory authority decision, change in opi[INVESTIGATOR_1100]/IEC, drug safety problems, or at the discretion of Aponia Laboratories, Inc.  In addition, Aponia Laboratories, Inc. retains the right to discontinue development of AP0302 5% at any time. 
If a study is prematurely terminated or discontinued, Aponia Laboratories, Inc. will promptly 
notify the investigator.  After notification, the investigator must contact [CONTACT_306635], Inc.  
 
Protocol Amendment 3 AP-007 Version: 02-Jul-2018 52 and the pharmacy (if applicable) within [ADDRESS_375435] extent possible. 
16 PUBLICATION OF STUDY RESULTS  
Please refer to the Clinical Study Agreement for the details and requirements for investigators interested in publishing the results of this study.   
CONFIDENTIAL  Aponia Laboratories, Inc.  
 
Protocol Amendment 3 AP-007 Version: 02-Jul-2018 53 17 REFERENCES  
CBI
CONFIDENTIAL  Aponia Laboratories, Inc.  
 
Protocol Amendment 3 AP-007 Version: 02-Jul-2018 54 
CBI
CONFIDENTIAL  Aponia Laboratories, Inc.  
 
Protocol Amendment 3 AP-007 Version: 02-Jul-2018 55 
CBI
CONFIDENTIAL   Aponia Laboratories, Inc.  
 
Protocol Amendment 3 AP-007 Version: 02-Jul-2018 56 Appendix 1 Schedule of Assessments 
 Screening Visit  Exercise Visit  Treatment Period  Follow -up 
Phone Call  
    
Day-28 to  
Day -3 Day -2 or -1 Day 7 
¬±1 day 
Informed consent  X       
Verify/re -assess eligibility  X X X     
Demographics  X       
Medical history  X X X     
Exercise history X X      
Record height and weight  X       
Record prior/current medications and non -medicinal 
therapi[INVESTIGATOR_014]  X X X X X X X 
Physical examination  X     X  
Physical examination  ‚Äì abbreviated/symptom directed 
only based on Screening1  X      
Vital signs (BP, HR, temperature, and RR)  X X X   X  
12-lead ECG  X     X  
Clinical laboratory tests (chemistry, hematology, 
coagulation, and urinalysis)  X     X  
Urine drug screen/ Alcohol breath test  X X X     
Pregnancy test (WOCBP) X X X     
 X       
Exercise regimen   X      
   
   
Muscle pain/soreness with movement Categorical Pain 
Rating Scale3    
PI-NRS , Muscle stiffness with movement NRS [ADDRESS_375436]‚Äôs global assessment of study medication6      X  
Adverse events     X X X X 
CBI
CBI
CBI
CBI
CONFIDENTIAL   Aponia Laboratories, Inc.  
 
Protocol Amendment 3 AP-007 Version: 02-Jul-2018 57 Abbreviations: BP = blood pressure; ECG = electrocardiogram; HR = heart rate; NRS = numerical rating scale; PI-NRS =Pain Intensity Numerical Rating Scale; RR = respi[INVESTIGATOR_697]; T 0 = time of first 
application of study drug; WOCBP = women of childbearing potential.  
CBI
CONFIDENTIAL      
 
Protocol Amendment 3 AP-007 Version: 02-Jul-2018 58 Appendix 2 NRS and Categorical Rating Scales  
 PAIN INTENSITY NUMERICAL RATING SCALE 
What number represents your muscle pain/soreness with movement? 	
	
No Pain      [ADDRESS_375437] describes your muscle pain/soreness with movement? 
‚ñ°		None (0)	
‚ñ°		Slight (1)	
‚ñ°		Moderate (2)	
‚ñ°		Severe (3)		
MUSCLE STIFFNESS NUMERICAL RATING SCALE  
Stiffness refers to how hard it is to flex and extend your arm. 
What number represents your muscle stiffness with movement? 
	
     No Stiffness      [ADDRESS_375438] describes your relief from starting pain? 
‚ñ°		No relief (0)	
‚ñ°		A little relief (1)	
‚ñ°		Some relief (2)	
‚ñ°		A lot of relief (3)		
‚ñ°		Complete relief (4)	 	
  
CONFIDENTIAL      
 
Protocol Amendment 3 AP-007 Version: 02-Jul-[ADDRESS_375439] you received? 
‚ñ°	Poor (0)	
‚ñ°	Fair (1)	
‚ñ°	Good (2)	
‚ñ°	Very Good (3) 
‚ñ°	Excellent (4) 
  
CONFIDENTIAL      
 
Protocol Amendment 3 AP-007 Version: 02-Jul-2018 60  
CBI